189 related articles for article (PubMed ID: 30617528)
1. [Systemic treatment of metastatic tumors of the upper urinary tract].
Darr C; Hadaschik BA; Tschirdewahn S
Urologe A; 2019 Jan; 58(1):30-33. PubMed ID: 30617528
[TBL] [Abstract][Full Text] [Related]
2. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
3. Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.
Kikuchi E; Miyazaki J; Yuge K; Hagiwara M; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Yamamoto S; Kinoshita H; Wakeda H; Hanai K; Nishiyama H
Jpn J Clin Oncol; 2016 Feb; 46(2):163-9. PubMed ID: 26657277
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
5. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
Calleris G; Rouprêt M; Seisen T; Bendjeddou L; Chevallier T; Masson-Lecomte A; Thibault C; Neuzillet Y; Audenet F; Xylinas E; Houédé N
World J Urol; 2023 Dec; 41(12):3413-3420. PubMed ID: 37698632
[TBL] [Abstract][Full Text] [Related]
6. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
Grossmann NC; Pradere B; D'Andrea D; Schuettfort VM; Mori K; Rajwa P; Quhal F; Laukhtina E; Katayama S; Fankhauser CD; Xylinas E; Margulis V; Moschini M; Abufaraj M; Bandini M; Lonati C; Nyirady P; Karakiewicz PI; Fajkovic H; Shariat SF
Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
11. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of methotrexate, vinblastine, doxorubicin and cisplatin adjuvant chemotherapy following radical surgery for locally invasive urothelial cancers: long-term results].
Tachibana M; Miyakawa A; Nakashima J; Nakamura K; Deguchi N; Baba S; Murai M; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1995 May; 86(5):1016-21. PubMed ID: 7596077
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
[TBL] [Abstract][Full Text] [Related]
15. [Advanced bladder cancer : From chemo- to immunotherapy].
Horn T; Krege S; Retz M
Urologe A; 2018 Jun; 57(6):686-692. PubMed ID: 29637216
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
17. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Pham MN; Apolo AB; De Santis M; Galsky MD; Leibovich BC; Pisters LL; Siefker-Radtke AO; Sonpavde G; Steinberg GD; Sternberg CN; Tagawa ST; Weizer AZ; Woods ME; Milowsky MI
World J Urol; 2017 Mar; 35(3):367-378. PubMed ID: 27342991
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].
Hupe MC; Kramer MW; Kuczyk MA; Merseburger AS
Aktuelle Urol; 2015 May; 46(3):242-7. PubMed ID: 26077309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
